Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...

A new study characterizes a bioengineered adeno-associated virus (AAV)3B capsid variant that demonstrates improved transduction to human liver cells. Another advantage of the AAV3B-V04 capsid was its ...

A new review tracks expanding chikungunya transmission, chronic sequelae, diagnostics, and prevention advances through 2025.

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

It was the summer of 2020. Pandemic aside, things were going well for Tuyen Ong, M.D. The physician and biotech entrepreneur was heading up the opthamology franchise unit of Biogen following its ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...